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Abstract
This review covers the isolation, total synthesis, biologic activity, and more particularly the in vitro and in vivo anti-
tumor activities of naturally occurring isocarbostyril alkaloids from the Amaryllidaceae family. Starting from these
natural products, new derivatives have been synthesized to explore structure–activity relationships within the
chemical class and to obtain potential candidates for preclinical development. This approach appears to be capa-
ble of providing novel promising anticancer agents.
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Introduction
Natural products have played a highly significant role in the discovery
and development of new drugs for the treatment of human diseases
[1]. This is particularly evident in the cancer field, where more than
60% of drugs are of natural origin [2]. Plants from the Amaryllidaceae
family have long been known for their medicinal and toxic properties.
Indeed even in ancient Greece, the oil from Narcissus species was al-
ready being used successfully for the treatment of cancer [3]. Conse-
quently, efforts have been made to isolate the active ingredients
responsible for this antitumor activity. Some 48 alkaloids bearing a va-
riety of carbon skeletons have been isolated from Narcissus species [4].
One small group of these alkaloids does not contain basic nitrogen
atoms and is represented by hydroxylated benzophenanthridone [5]
or isoquinolinone types of structure. The most widely known com-
pounds [5] of this group are narciclasine 1, lycoricidine 2, and pancra-
tistatin 3 (Figure 1), and the most frequently used term in the
literature to describe this group of alkaloids is the isocarbostyrils [6,7].
All these natural products have demonstrated potent in vitro cyto-
toxicity against cancer cell lines [7] and potent in vivo antitumor ac-
tivity against mouse M-5076 sarcoma and P388 leukemia [7].
Therefore, this family as a whole seems of interest as a potential
source of new lead structures for the development of a future gener-
ation of anticancer drugs.
This review focuses on the isocarbostyril alkaloid family, with a
special emphasis on the isolation and synthesis of these natural prod-
ucts and their hemi- and fully synthetic derivatives and their in vitro
and in vivo antitumor activity. Finally, recent advances in understand-
ing the mechanism of action of these antitumoral molecules as well as
their original role in the control of the plant growth will be discussed.
Isolation of Amaryllidaceae
Isocarbostyril Alkaloids
Narciclasine and Natural Derivatives
Narciclasine 1, also known as lycoricidinol given it is the 7-hydroxy
derivative of lycoricidine 2 (Figure 1), was the first alkaloid of the class
isolated in 1967 from Narcissus (Amaryllidaceae species) bulbs based
on its inhibition of the growth of wheat grain radicles [8]. The typical
procedure for the isolation of this compound involves ethanolic extrac-
tion of fresh daffodil bulbs. The alcohol is then evaporated to leave an
aqueous residue, which is itself extracted with dichloromethane to re-
move nonpolar contaminants. Narciclasine is then extracted from the
residual aqueous phase with ethyl acetate. After evaporation of the sol-
vent, the residue is dissolved in ethanol, and after that, solid deposit
was further purified by column chromatography [8,9]. Narciclasine is
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obtained as a pure product after alcohol or acetic acid crystallization
(as light yellowish needles) of the eluted fraction containing the
compound. The structure of narciclasine was elucidated in 1970 by
1H nuclear magnetic resonance (NMR) and 13C NMR, mass spectral,
infrared, and elemental analyses and was further characterized with re-
spect to optical rotation [9,10].
One of the most widely reported sources of narciclasine is the
bulbs of Narcissus species [4,8,11]. Thirty-two species and varieties
of this genus have been examined for narciclasine content, which var-
ies from 30 to 200 mg/kg fresh bulbs. The typical content in this
genus is 100 to 120 mg/kg (Table 1) and may vary during the year.
For example, a content of 200 mg/kg was exceptionally found in
bulbs of Narcissus incomparabilis Mill. Var. Helios at the flowering
stage in March (Table 1). The occurrence of narciclasine was also in-
vestigated in others species of Amaryllidaceae, including Lycoris radiata
[12,13], Haemanthus [6,11], Hymenocallis [7,11,14,15], Brachystola
magna [16], Galanthus [11], Leucojum [11], Pancratium maritimum
[11], Sprekelia formosissima [11], Sternbergia lutea [11], and Vallota
speciosa [11]. The content of narciclasine in these species does not ex-
ceed 50 mg/kg fresh bulbs (Table 1). Narciclasine was exceptionally
found in high concentrations (∼135 mg/kg) in Zephyranthes flava, a
tropical and subtropical plant cultivated in India (Table 1) [6].
However, in general and based on analyses to date, Narcissus bulbs
are the best and easiest to obtain source of narciclasine, given that
these plants are relatively common and can grow in many countries
with different climates.
The biosynthesis of these Amaryllidaceae alkaloids in plants was
deciphered in 1971 [17]. Narciclasine is synthesized from O-methyl-
norbelladine 4 by para–para phenol coupling to obtain vittatine 5 as
an intermediate (Scheme 1) [17,18]. Subsequent elimination of two
carbon atoms and hydroxylations of compound 5 then leads to narci-
clasine (Scheme 1).
In 1985, the first biosynthetic derivative of narciclasine, com-
pound 6 (Figure 2), was isolated in good quantities from Haemanthus
kalbreyeri [19] and Z. flava [20] (concentrations of 78 and 165 mg/
kg, respectively), two tropical and subtropical Amaryllidaceae species.
So this natural product was named kalbreclasine, and it is the 2-O-β-
D-glucopyranoside derivative of narciclasine. This compound, whose
structure was fully elucidated by spectroscopic and chemical meth-
ods, provoked a significant activation of splenic lymphocytes in vitro,
a feature characteristic of immunostimulants [19]. Another β-D-
glucoside derivative of narciclasine 7 (Figure 2) was isolated in 1991
in trace amounts from P. maritimum (∼3.5 mg/kg) [21]. Currently, the
last known natural derivative of narciclasine (Figure 2) isolated is trans-
dihydronarciclasine 8, which is extracted at low levels (11 mg/kg) from
Zephyranthes candida [22].
Lycoricidine and Natural Derivatives
7-Deoxynarciclasine 2 (Figure 1), more generally known as lyco-
ricidine, was first discovered in L. radiata in 1968 [12]. The product
was isolated from methanol extracts of the plant’s bulbs by a similar
procedure to that used for narciclasine. Lycoricidine, which was ob-
tained only at low levels (∼3 mg/kg; Table 1), was found similar to
narciclasine to be a plant growth inhibitor [12]. The structure of
lycoricidine was fully established particularly by 1H NMR and 13C
NMR and by chemical reactions [12,23]. Lycoricidine and narcicla-
sine were shown in 1983 to have a potent insecticidal action, in ad-
dition to reducing feeding activity in the larvae of certain butterfly
species [13].
Lycoricidine was also isolated in low quantities (∼17 mg/kg) from
H. kalbreyeri [6] and in moderate quantities (∼32 mg/kg) from
Ismene × “Sulphur Queen” [15]. The best sources of lycoricidine are
bulbs of Hymenocallis littoralis collected from the wild in Hawaii
as these yield in the order of 118 mg/kg [14,24]. However, if this
rare tropical plant is cultivated in Arizona, the content of lycoricidine
is much reduced, varies during the year, and only a maximum of
15 mg/kg can be isolated even in the peak month of October [14].
This difference in the content to the native Hawaiian bulb could
be explained by an Arizona climate that is much hotter, drier, and
sunnier [14].
Figure 1. Chemical structures of narciclasine, lycoricidine and pancratistatin.
Table 1. Occurrence of Narciclasine 1, Lycoricidine 2, and Pancratistatin 3 (in mg/kg of Bulbs or
Seeds) in Some Amaryllidaceae Species.
Amaryllidaceae Species Compounds
1 2 3
N. imcomparabilis 200 in March NI NI
100-120 in November
Narcissus “Carlton” 100-120 NI NI
H. kalbreyeri 45 17 157
Z. flava 135 NI 165
P. maritimum 50 NI 6
L. radiata 4.2 3.2 NI
Ismene × “Sulfur Queen” NI 32 NI
H. littoralis 5 118 100-150 from Hawaii
22 from Arizona
B. magna 1.5 NI 2.5
Z. carinata NI NI 7.5
NI indicates not isolated.
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To date, only one natural derivative of lycoricidine 9 (Figure 3)
has been isolated from H. littoralis [14,23,25] (the tropical spider
lily) and Hymenocallis caribaea [7]. Compound 9 (7-deoxy-trans-
dihydronarciclasine or alternatively trans-dihydro lycoricidine) is a
trans-dihydro derivative of lycoricidine in which the two ring cy-
cles are trans linked. Hymenocallis littoralis contains a maximum of
16 mg/kg of 9 when sampled in October [14], whereas H. caribaea
contains a maximum of only 3.8 mg/kg. The structure has been fully
elucidated by spectroscopic and chemical methods [7,25].
Pancratistatin and Natural Derivatives
In 1984, pancratistatin 3 (Figure 1) was first discovered in a Hawaiian
species originally designated as Pancratium littorale, but later reclassi-
fied as H. littoralis [26]. The bulb section of this native Hawaiian
plant was extracted with dichloromethane–methanol–water and
the extract was concentrated to obtain an aqueous phase. Organic
compounds were extracted with n-butanol and purification of the re-
sulting crude product was undertaken using gel permeation chroma-
tography (Sephadex LH-20) and precipitation/crystallization to give
the pure natural product 3 [26]. This experimental procedure is very
effective for laboratory-scale isolation of pancratistatin, but for large-
scale production, the cost is too high. Another procedure was then
developed to avoid the use of gel permeation, but this approach re-
mains more complicated than the isolation of narciclasine [14].
The structure of pancratistatin was fully elucidated by 1H NMR
and 13C NMR, mass spectrometry, infrared, and elemental analyses
[24,26] and was corroborated by an X-ray crystal structure determi-
nation of the hemisynthesized 7-methoxy derivative [26]. As with
narciclasine and lycoricidine, pancratistatin has been found to exhibit
strong in vitro RNA antiviral activity [27]. In vivo, pancratistatin in-
creased survival by 100% when it was used to treat mice infected
with Japanese encephalitis [27]. Furthermore, this product showed
activity against two other RNA-containing flaviviruses and bunya-
viruses, namely Punta Toro and Rift Valley fever [27]. Pancratistatin
and lycoricidine also showed an in vitro antiparasitic effect against a
microsporidium causing infections in humans [28].
The rare tropical bulbs of H. littoralis seem to be a good source of
pancratistatin as it can be isolated from these in the order of 100 to
150 mg/kg when bulbs are obtained from the wild in Hawaii (Table 1)
[14,24]. However, the compound has to be commercially extracted from
field- and greenhouse-grown bulbs or from tissue cultures cultivated, for
example, in Arizona, which generate lower levels of pancratistatin (a
maximum of 22 mg/kg) even in the peak month of October (Table 1)
[14]. After October, when the bulb becomes dormant, levels of pancra-
tistatin drop to only 4 mg/kg by May [14]. Field-grown bulbs, which
show monthly changes in pancratistatin content, generate somewhat
smaller amounts (2-5 mg/kg) compared to those grown in greenhouse
cultivated over the same period [14]. The occurrence of pancratistatin
has also been investigated in other Amaryllidaceae, including several spe-
cies of Hymenocallis [15], B. magna [16], and P. maritimum [15]. The
pancratistatin content of these species does not exceed 29 mg/kg of fresh
bulbs. Pancratistatin was exceptionally found in good quantity in Z. flava
[20] and H. kalbreyeri [6] (Table 1), two tropical and subtropical plants
cultivated in India. Consequently and to date, the best sources of pancra-
tistatin are rare, tropical, and subtropical bulbs of Z. flava, H. kalbreyeri,
and H. littoralis when these plants are cultivated in their native region.
Scheme 1. The biosynthesis of narciclasine.
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The first natural derivative of pancratistatin, compound 10 (Fig-
ure 4), was isolated from H. kalbreyeri in 1989 [6]. This 2-O-β-
D-glucopyranoside derivative, pancratiside, was found to promote the
germination of seeds and the growth of roots similar to kalbreclasine
6 but unlike its aglycone derivatives [6]. 7-Deoxy-pancratistatin 12
(Figure 4) was also discovered in the same plant in small amounts
(∼30 mg/kg) [6]. The structures of these two alkaloids were established
by comprehensive spectral analyses and chemical transformations [6].
Another glycoside derivative, telastaside 11 (Figure 4), was also isolated
from this family of plants [29]. In 1998, two new derivatives of pancra-
tistatin 13 and 14 (Figure 4) were extracted in moderate amounts (24
and 44 mg/kg, respectively) from Zephyranthes carinata [30]. Key sub-
stituents in these two molecules were identified as a 3-hydroxy-butyryl
group for compound 13 and as a 3-O-glucosylated butyryl group for
derivative 14 [30]. The structures of these two natural products were
established by 1D and 2D NMR spectral analyses [30].
Synthesis of Isocarbostyril Alkaloids
In general, these alkaloids are isolated only in moderate quantities
from natural sources. As they have revealed promising antitumor ac-
tivities (Sections 4 and 5), there is a strong need to develop total syn-
theses of these alkaloids and their derivatives to obtain them more
easily and in appreciable quantities. There are more than 25 refer-
ences on this subject revealing these syntheses to be complex multi-
step processes. The full synthesis of these alkaloids has been reviewed
on several occasions [31,32], and the focus here will be on represen-
tative syntheses for narciclasine, lycoricidine, and pancratistatin.
Narciclasine and Lycoricidine
One of the shortest synthetic routes for narciclasine and lycorici-
dine was established by Rinner and Hudlicky [31] and Hudlicky
et al. [32]. The key product of this synthesis was the cyclohexadiene
diol 16 (Scheme 2) obtained by the whole-cell fermentation of 1,3-
dibromobenzene 15 with recombinant Escherichia coli JM0109 [33].
This diol 16 was then protected by an acetonide group, and the re-
sulting product subject to a hetero–Diels-Alder reaction to generate
Figure 2. Natural derivatives of narciclasine.
Figure 3. Chemical structure of the only one isolated natural de-
rivative of lycoricidine.
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Figure 4. Chemical structures of natural derivatives of pancratistatin.
Scheme 2. a:E. coli JM109 (pDTG601A), 4 g/L. b: i) DMP, acetone,p-TsOH, r.t.; ii) NHCO2Me,NaIO4, r.t., 70%. c:borate 18, Pd(PPh3)4, aqNa2CO3,
PhH, reflux, 30%. d: TTMSS, AIBN, PhH, reflux, 80%. e:NaBH4, CeCl3, MeOH, 0°C, 80%. f: BzOH, Bu3P, DEAD, THF, r.t., 65%. g: i) Dowex 50X8-
100, MeOH, r.t.; ii) Ac2O, pyridine, DMAP, r.t., 70%. h: Tf2O, DMAP, CH2Cl2, 0°C, 40%. i: i) Amberlyst A21, MeOH; ii) LiCl, DMF, 120°C, 20%.
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oxazine 17. A Suzuki coupling of one of the bromines on 17 with the
boronic acid derivative 18 afforded the desired coupled product, which
was treated with a silylsilane derivative to form the ketone 19. The
reduction of the ketone function was followed by a Mitsunobu reac-
tion to obtain benzoate 20. After replacement of the acetonide by ace-
tates, a modified Bischler–Napieralski ring-closure gave the protected
product 21. Cleavage of the phenolic methyl function and removal of
protecting groups afforded narciclasine 1 in 12 steps with an overall
yield of 0.5% from the cyclohexadiene diol 16. The synthesis of lyco-
ricidine 2 was realized in nine steps (30% overall yield) by the same
method using a cyclohexadiene diol such as 16 obtained by biooxida-
tion with the same bacteria E. coli [34].
A second method of synthesis used for narciclasine and lycorici-
dine was established in 1999 by Keck as reviewed in the work of
Rinner and Hudlicky [31]. The starting material of these total syn-
theses is the commercially available D-gulonolactone 22 that fits cor-
rectly with three of the four stereocenters of these isocarbostyril
products (Scheme 3). After 2,3-acetonide protection, compound 23
was obtained in two steps. Oxidation of 23 followed by a Corey–Fuchs
reaction of this latter product gave dibromide 24. The lactone function
of 24 was then converted to the O-benzyl amine derivative 25. A
Pd-catalyzed coupling reaction of 25 with compound 26 provided
the alkyne 27. The radical cyclization of this latter product afforded
compound 28 with an 88% yield. Cleavage of the tosyl group in
28 and methylation of the phenolic hydroxyl functionality allowed
aluminum-catalyzed cyclization to deliver the protected product 29.
Deprotection of the thioether and removal of acetonide by acid treat-
ment afforded narciclasine 1 in 14 steps from D-gulonolactone with
an overall yield of 16%. This method of synthesis was also used for
lycoricidine in 11 steps with an overall yield of 27% starting from
D-gulonolactone 22 and the appropriate aromatic analog of 26 [31].
Pancratistatin
Danishefsky et al., as reviewed in the work of Rinner and Hudlicky
[31], reported in 1989 the first total synthesis of racemic pancratista-
tin. Thereafter, numerous research groups published the stereoselective
synthesis of pancratistatin. These syntheses were previously reviewed
[31] and include those of Tian et al. [35], Doyle et al. [36], Trost
and Pulley [37], Rigby et al. [38], Magnus and Sebhat [39], and Ko
et al. [40]. Another interesting synthesis of pancratistatin was reported
in 2006 by Li et al. [41] and started from pinitol 30 whose stereogenic
centers exactly match those of the C-ring of pancratistatin (Scheme 4).
Protection of the diol functions of compound 30 gave compound 31.
The free hydroxyl of this was subsequently substituted by an azide to
give 32. After removal of the silyl function, a cyclic sulfate was installed
to obtain product 33. The Staudinger reaction gave the free amine 34
from azide 33. The coupling reaction between 34 and 35 gave com-
pound 36 with a moderate yield. Methocymethyl protection of both
Scheme 3. a: DMP, p-TsOH, DMF, 79%. b: AcOH, H2O, THF, 79%. c: NaIO4, CH2Cl2. d: CBr4, PPh3, Et3N, 80% (more than two steps). e:
L-Selectride, Et2O, −78°C. f: HCl·H2NOBn, pyridine, 90% (more than two steps). g: n-BuLi, Et2O, −90°C, 93%. h: Pd(OAc)2, PPh3, CuI,
Et3N, 26, THF, 89%. i: PhSH, hn, toluene, 27°C, 88%. j: SmI2, THF, H2O, 0°C, 94%. k: MeI, K2CO3, DMF, 96%. l: Me3Al, THF, −15°C to
65°C, 72%. m: SmI2, MeOH, THF, 0°C, 87%. n: TFA, 0°C, 89%.
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the amide and the free phenol gave compound 37. Treatment of this
latter product with t-BuLi followed by addition of cerium chloride
gave compound 38. Full deprotection of 38 by BBr3 and methanol
afforded pancratistatin 3 in 12 steps from commercially available pini-
tol with an overall yield of 2.3%.
Given the higher availability of narciclasine in extracts of Narcissus
species (up to 200 mg/kg), Pettit et al. [42,43] have developed and pat-
ented a second process to synthesize pancratistatin from Amaryllidaceae-
derived narciclasine. The hydroxyl functions of narciclasine are first pro-
tected and the olefin function oxidized to give epoxide 39 (Scheme 5).
Hydrogenation of this latter product and subsequent saponification
yields a mixture of four compounds, one of which is the desired diol 40.
Activation of this diol with thionyl chloride and oxidation of the epi-
meric sulfites give the cyclic sulfate 41. Nucleophilic opening of com-
pound 41 and hydrolysis of the sulfate and acetonide functions affords
the benzoate product 42. Deprotection of the benzoyl group at C-1
position gives pancratistatin 3 in 10 steps and an overall yield of
3.6% from narciclasine 1.
In Vitro Antitumor Activity
Narciclasine, Lycoricidine, Pancratistatin,
and Natural Derivatives
The cytotoxicity of these isocarbostyril alkaloids was first demon-
strated in basic assays some 30 years ago [12,44] and later confirmed
in standard MTT colorimetric assays on diverse human tumor cell
lines by the National Cancer Institute (NCI) [7,23,45,46].
Narciclasine 1 exhibits in vitro potent cytotoxicity against human
cancer cell lines and murine P388 leukemia cells (Table 2) [45,46].
The cytotoxicity of this product was evaluated in 60 cancer cell lines
by the NCI, and the mean IC50 value (the concentration which in-
hibits overall cell growth in culture by 50%) was 0.046 μM [45].
With respect to narciclasine, lycoricidine 2 demonstrates cytotoxic
activity against these 60 cancer cell lines, which is ∼10 times weaker
(mean IC50 = 0.33 μM), and pancratistatin 3 an activity ∼5 times
weaker (IC50 = 0.26 μM) [46]. The observed cytotoxicity of these three
isocarbostyrils against murine P388 leukemia cell line is similar but re-
sults against human cancer cell lines (Table 2) confirm those found by
the NCI for lycoricidine but not for pancratistatin [23,45]. Against the
murine P388 leukemia cell line, dehydronarciclasine 8 showed more
potent cytotoxicity than narciclasine (Table 2), but in the 60 cancer cell
line panel, the cytotoxicity was of the same order of magnitude with a
mean IC50 of 0.053 μM [23,45,46]. Dehydrolycoricidine 9 revealed
the same level of cytotoxicity as lycoricidine (Table 2) [23]. These re-
sults with compounds 8 and 9 revealed that the double bond between
the C-1 and C-10b is not essential for the cytotoxicity of these isocar-
bostyril alkaloids. For glycoside derivatives 6, 7, 10, and 11 (Figures 2
and 4), there are no data in the literature on the cytotoxicity measured
by MTTassays against cancer cells. However, for glucoside derivative 7,
a potato disc cytotoxicity assay has revealed an activity very similar to
Scheme 4. a: TIPDSCl2, imidazole, DMAP, DMF, 24%. b: DMP, p-TsOH, acetone, 81%. c: PPh3, DEAD, CH3SO3H, CH2Cl2, 0°C to r.t. then
NaN3, DMF, 60°C, 72%. d: TBAF, THF, 0°C to r.t., 100%. e: SOCl2, Et3N, CH2Cl2, 0°C. f: NaIO4, RuCl3, aq CH3CN, 87% (more than two
steps). g: PPh3, aq THF, 0°C to r.t., 94%. h: Et2O, 35, 0°C, 64%. i: K2CO3, MOMCl, DMF, 84%. j: t-BuLi, CeCl3, ultrasound, THF,−78°C to r.t.,
72%. k: BBr3, CH2Cl2, −78°C to 0°C, 1 hour then MeOH, −78°C to 0°C, 2 hours, 52%.
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narciclasine [21]. For 7-deoxy pancratistatin 12, only two cancer cell
lines have been tested and this product demonstrated a 10- to 20-fold
lower cytotoxic activity than pancratistatin (Table 2) [47]. It can be
concluded that the phenolic hydroxyl group of compounds 1 and 3
contributes to the greater (≥10-fold) activity of these products com-
pared to that of their congeners 12 and 2.
The hydroxybutyril derivative of pancratistatin 13 gave two-fold
better cytotoxicity than pancratistatin against P388 leukemia cells
[30]. This better activity was then confirmed by the NCI in the 60–
cancer cell line panel with a mean IC50 of 0.037 μM [46]. The gluco-
side derivative 14 revealed the same order of cytotoxicity as pancratis-
tatin against P388 leukemia cells [30].
Fully and Hemisynthesized Derivatives
A series of derivatives and analogs have been synthesized by full or
hemisynthesis to obtain more active and/or soluble products (Figure 5)
that could be potentially selected for preclinical development as anti-
cancer agents.
Only one compound that has been synthesized, a derivative of nar-
ciclasine (Scheme 5) [42,43], has been found to be more active than
pancratistatin. This 1-benzoate pancratistatin derivative 42, phenpan-
statin, has revealed a cytotoxicity 10 times higher than pancratistatin 3
against a panel of human cancer cell lines (Tables 2 and 3) [45].
Naturally occurring isocarbostyril alkaloids such as pancratistatin
have low aqueous solubility (∼50 μg/ml) [45]. This has limited their
clinical evaluation in intravenous formulations. To increase aqueous sol-
ubility, phosphate prodrugs, which release the active drug through the
action of cellular phosphatases, have been synthesized [23,45,48]. Sev-
eral positions (4-OH, 7-OH, and 3,4-OH) on the natural isocarbostyril
alkaloids were used to obtain 3,4-cyclic phosphate derivatives 43,
44, 45, 50 (7-O-phosphate pancratistatin), 51 (4-O-phosphate pan-
cratistatin), 52, 53 (narcistatin), and 54 (Figure 5) [23,45,48]. These
Scheme 5. a: DMF, DMP, p-TsOH, 97%. b: Ac2O, pyridine, 81%. c: m-CPBA, phosphate buffer, CH2Cl2, H2O, 52%. d: i) H2, Pd/C 10%; ii)
K2CO3, MeOH, H2O, 28%. e: SOCl2, Et3N, THF; f: RuCl3·3H2O, NaIO4, MeCN, CCl4, H2O, 47% (more than two steps). g: i) PhCO2H,
CsCO3, DMF; ii) THF, H2O, H2SO4, 74%. h: K2CO3, MeOH, 75%.
Table 2. In Vitro Cytotoxic-Related Antitumor Effects (IC50 Values in μM)* of Certain Naturally Occurring Isocarbostyril Alkaloids [23,44].
Compounds Cancer Cell Lines
Leukemia P388 Pancreas BXPC-3 Breast MCF-7 CNS SF268 Lung-NSC NCI-H460 Colon KM20L2 Prostate Du-145
1 0.042 0.011 0.010 0.010 0.027 0.011 0.011
2 0.065 0.24 0.16 0.41 0.18 0.29 0.17
3 0.052 0.061 0.071 0.043 0.098 0.077 0.046
8 0.0078 0.039 0.017 0.065 0.030 0.049 0.021
9 0.099 0.16 0.12 0.20 0.15 0.17 0.14
12 1.42 NT NT NT NT 0.71 NT
*Data are initially given in μg/ml [50% effective dose (ED50) or 50% growth inhibition (GI50)].
NT indicates not tested.
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phosphate derivatives had considerably improved aqueous solubility, no-
tably the sodium salt of narcistatin 53 (60 mg/ml) and have been duly
patented [49–52]. All phosphate derivatives have markedly lower cyto-
toxicity in vitro compared to their active parent compound (Tables 2
and 3) [23,45,48]. However, as indicated above, hydrolysis of the phos-
phate groups to release the active isocarbostyril is expected to be very ef-
fective in vivo. In vivo antitumor evaluations will be undertaken shortly
to validate this concept of water-soluble phosphate prodrugs [23].
Figure 5. Chemical structures of fully and hemisynthesized isocarbostyril derivatives.
Table 3. In Vitro Cytotoxic-Related Antitumor Effects (IC50 Values in μM)* of Fully and Hemisynthetic Isocarbostyril Alkaloid Derivatives.
Compounds Cancer Cell Lines
Leukemia P388 Pancreas BXPC-3 Breast MCF-7 CNS SF268 Lung-NSC NCI-H460 Colon KM20L2 Prostate Du-145
42 0.0037 0.0044 0.00072 0.0013 0.00023 0.00086 0.00049
43 8.1 8.1 7.1 7.1 9.3 9 5.6
44 4.2 > 26.5 19.1 > 26.5 > 26.5 > 26.5 > 26.5
45 2.2 14.2 11.7 22.4 19.8 24.4 13.2
46 10.5 4.4 5.4 5.1 2.5 5.4 2.2
47 5 > 36.1 > 36.1 > 36.1 > 36.1 > 36.1 > 36.1
48 1.6 NT NT NT NT NT NT
49 153.6 NT NT NT NT NT NT
50 0.53 0.44 0.44 0.18 0.42 0.38 0.058
51 0.042 0.42 0.42 0.28 0.89 0.56 2.2
52 0.12 0.49 0.08 0.33 0.056 0.25 0.25
53 0.031 0.18 0.15 0.12 0.15 0.15 0.08
54 4.5 14.1 10.7 16.8 12.5 14.9 10.4
55 22.6 14 10.8 9.2 10.8 > 32 > 10.2
56 < 0.03 0.78 0.72 0.57 0.96 0.54 0.78
57 14.6 16.6 14.9 11.2 9.5 12.2 8.8
58 60.2 > 32.9 > 32.9 NT NT > 32.9 NT
*Data are initially given in μg/ml (ED50 or GI50).
NT indicates not tested.
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To explore the structure–activity relationship (Figure 5 and Tables 2
and 3) of these isocarbostyril alkaloids, several other key positions in
the molecule were modified. One modification involved the reduction
of the lactam carbonyl group. For this purpose, 2-acetate lycoricidine
56 (Figure 5) was synthesized as an intermediate, but this modification
was found to have a low impact on cytotoxicity. In contrast, com-
pounds 46 and 55 (Figure 5) were found to be inactive against the
panel of human cancer cell lines (Table 3) [25]. Fully synthetic com-
pounds 59 and 60 (Figure 5) in which the lactam carbonyl was also
replaced by a lactone function, which is considered an analog [5],
showed no significant cytotoxic activity against L1210 murine leuke-
mia cells [5]. All these modulations appear to indicate that the lactam
carbonyl function is essential for cytotoxic activity.
Three deoxy-analogs of these isocarbostyril alkaloids 47, 48, and
49 (Figure 5) were synthesized to determine the minimum structural
pharmacophore [53,54]. These three analogs showed weak antitumor
activity (Table 3) and so revealed that the C-2, C-3, and C-4 hydroxyl
groups were essential for the cytotoxic activity and can be considered as
a minimum pharmacophore [53,54].
Another modulation was the B/C ring junction stereochemistry
(Figure 1) and was evaluated through the synthesis of derivatives 61,
62, and 63 (Figure 5) [7,55]. For the isonarciclasine 61, the B/C ring
junction is planar because a double bond connects the two rings. A cis–
B/C ring junction was obtained in products 62 and 63 after hydroge-
nation or oxidation of the double bond of narciclasine [7,22]. All these
products showed weaker cytotoxicity than the parent natural com-
pounds. Compound 61 gave an IC50 in the order of 12 μM and
62 an IC50 of ∼4 μM [7]. The cytotoxicity of compound 63 against
P388 murine leukemia and several human cancer cell lines was found
to be about 1000 times less potent than pancratistatin [55]. All these
results appear to confirm the need for a trans–B/C ring junction in
these compounds to maintain potent cytotoxicity.
Modulation of the benzodioxole moiety of pancratistatin was inves-
tigated through the full synthesis of analogs 57 and 58 (Figure 5)
[47,54]. The methoxy analog 57 and the β-carboline-1-one derivative
58 were revealed to be 100-fold less cytotoxic than the corresponding
natural product [47,54]. These results show that an intact methylene-
dioxyphenyl or benzodioxole functionality is essential for significant
cancer cell cytotoxicity in this class of natural compounds.
In Vivo Antitumor Activity
Pancratistatin and narciclasine have proven to be effective in mu-
rine P388 lymphocytic leukemia and M-5076 ovary sarcoma models
in vivo [24]. Table 4 (A and B) shows the in vivo survival values from
the NCI database [46] for the antitumor activities of pancratistatin
(A) and narciclasine (B) in different mouse models. The T/C index
represents the percentage survival ratio of drug-treated (T ) compared
to untreated (C ) mice. A T/C value >125% indicates that drug treat-
ment significantly enhances the survival of the tumor-bearing mice.
The promising antineoplastic activity of pancratistatin has led to
its preclinical development and selection as an important synthetic
starting point for a growing number of research groups. Pancratista-
tin is particularly attractive for clinical development because of its
potent activity against experimental melanoma and ovary carci-
noma. Unfortunately, pancratistatin exhibits very low water solubility
(53 μg/ml) and this property has complicated its formulation for
intravenous administration. Although the solubility of this isocarbos-
tyril can be increased in organic solvents, such as dimethylformamide
and dimethylsulfoxide, and lower boiling aliphatic alcohols, their use
as formulation components is not desirable.
Mechanism of Action
Little is known regarding the anticancer mechanism of action of
this family of compounds. Narciclasine and lycoricidine were first
identified as plant growth inhibitors [8,12]. In plants, there is clear
evidence that narciclasine inhibits the synthesis of proteins and the
development of chloroplasts. Additionally, the compound isolated
from the mucilage of Narcissus bulbs showed inhibitory effects on
the growth and plastid development in excised radish cotyledons
[56]. Narciclasine (0.1 μM) starts to show inhibitory effects on
plant isocitrate lyase and hydroxypyruvate reductase activities after
24 hours of incubation in light. When the concentration is increased
to 10 μM, the activities of both enzymes are completely inhibited
[56]. From ultrastructure studies, 1 μM narciclasine markedly pre-
vents the degradation of protein bodies and lipid bodies, as well as
totally preventing chloroplast formation in excised radish cotyledons
[56]. Visible symptoms of tepal senescence in cut Iris × “Hollandica”
(cv. Blue Magic) flowers are delayed by placing one cut daffodil
flower (Narcissus pseudonarcissus, cv. “Carlton”) in the same vase
Table 4. National Cancer Institute Pancratistatin (A) and Narciclasine (B) In Vivo Antitumor Ac-












Tumor Site Inoculation i.p. i.p. i.p. i.p. s.c.
0.18 NT NT 113% 153% 101%
0.25 NT NT NT NT 106%
0.37 NT NT 122% NT NT
0.38 NT 120% 119% NT NT
0.5 NT NT NT NT 112%
0.75 NT 122% 139% 159% 106%
0.78 NT NT 133% 132% NT
1 NT NT NT NT 109%
1.5 100% 121% 142% 166% 111%
1.56 108% 131% 144% 129% NT
2 NT NT NT NT 112%
3 103% 133% 161% 184% 125%
3.12 129% 131% 151% 143% NT
4 NT NT NT NT 113%
6 114% NT 165% 177% 126%
6.25 110% NT 173% 152% NT
8 NT NT NT NT 121%
12 NT NT 156% 144% NT
12.5 NT NT 203% NT NT
24 NT NT NT Toxic NT












Site of Inoculation i.p. i.p. i.p. i.p. i.v.
0.62 115% 110% 110% NT 93%
1.25 111% 108% 129% NT 109%
2.5 109% 113% 162% NT 117%
3 NT NT NT 133% NT
5 123% 115% 100% NT NT
6 NT NT NT 160% NT
10 NT NT 87% NT NT
12.5 NT NT NT NT NT
All compounds were administrated intraperitoneally.
i.p. indicates intraperitoneal; i.v., intravenous; NT, not tested; s.c., subcutaneous.
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[57]. Addition of mucilage, exuded by daffodil stems to the vase water
has the same effect as the flowering daffodil stem. The active com-
pound in the mucilage was identified as narciclasine. This delay of
senescence by narciclasine correlates with a delayed increase in pro-
tease activity and marked reduction in maximum protease activity
[57]. Narciclasine, although not affecting in vitro protease activity,
is known to inhibit protein synthesis at the ribosomal level. Narcicla-
sine was also originally described as an antimitotic substance display-
ing colchicine-like effects [8]. It was also found to be an inhibitor of
peptide bond formation in eukaryotic ribosomes given its ability to
bind to the 60-S ribosomal subunit and more precisely to the peptidyl-
transferase center [58,59]. Furthermore, unlike many other anti-
cancer drugs, narciclasine has been found not to interact or form a
complex with DNA [60]. More recently, McLachlan et al. [61] dem-
onstrated that pancratistatin, whose chemical structure is very close
to that of narciclasine, induced rapid apoptosis in neuroblastoma
cells accompanied by disruption of the mitochondrial membrane po-
tential. Additionally, a decrease in ATP synthesis and an increase in
the production of reactive oxygen species, indicative of a dysfunction
of the mitochondrial respiratory chain, were observed in intact mito-
chondria incubated with the molecule [61]. These changes were not
observed in normal fibroblasts [61,62] and normal endothelial cells
[63]. Caspase-3 activation and exposure of phosphatidyl serine on
the outer leaflet of the plasma membrane were earlier events than
the generation of reactive oxygen species and DNA fragmentation
observed following pancratistatin treatment of cancer cells [64]. By
investigating isolated mitochondria, McLachlan et al. [61] demon-
strated that pancratistatin acted directly on mitochondria and con-
firmed that this effect was selective for mitochondria isolated from
cancer cells. Quite recently, Griffin et al. [62] undertook a synthetic
structure–activity relationship evaluation, which indicated that the mini-
mum cytotoxic pharmacophore of pancratistatin comprises the trans-
fused B/C ring system containing the 2,3,4-triol unit in the C-ring.
The results of their study further indicated that the phenanthridone
skeleton in natural Amaryllidaceae alkaloids may be a significant com-
mon element for selectivity against cancer cells [62]. McNulty et al. [65]
have previously demonstrated that a 2,3,4-triol–functionalized ring-C
is required as the minimum pharmacophoric element for potent anti-
cancer activity of pancratistatin.
We have recently reported that narciclasine shows potent in vitro cyto-
toxic activity against six different human cancer cell lines. In contrast,
normal human lung fibroblasts appear to be markedly less sensitive to
the molecule with a mean cytotoxic IC50 value (the concentration that
reduces by 50% the number of viable cells after 3 days of treatment) of
7.5 μM compared to 0.03 μM for the six human cancer cell lines [66].
The cytotoxic activity of narciclasine was similar in the six cancer cell
lines investigated, a feature consistent with NCI data that revealed a
mean IC50 value of 0.046 μM for the compound across a panel of
60 cancer cell lines, including doxorubicin-resistant cancer cells [46].
Additionally, based on comparative evaluations assessing morphologic
changes, after internucleosomal DNA fragmentation or the externaliza-
tion of phosphatidyl serine in normal fibroblasts and in human cancer
cells, the proapoptotic effects of narciclasine at concentrations up to
1 μM were confined to cancer cells [66]. These results collectively em-
phasize the marked selectivity of narciclasine for cancer cells, as also
demonstrated by Griffin et al. [62] for pancratistatin. We have shown
that the narciclasine-induced apoptosis-mediated cytotoxic effects in
human cancer cells not evident in normal fibroblasts is paralleled by
the triggering of the activation of the initiator caspases of the death re-
ceptor pathway (caspase-8 and -10), at least in human MCF-7 breast
and PC-3 prostate carcinoma cells. This is a feature not observed in
normal human fibroblasts [66]. Indeed, formation of the Fas and
DR4 death-inducing signaling complex was clearly evidenced in
MCF-7 and PC-3 cancer cells [66]. Additionally, in these two cancer
cell lines, caspase-8 was found to interact with the Fas and DR4 re-
ceptors on narciclasine treatment. However, after this initial step,
narciclasine-induced downstream apoptotic pathways in MCF-7 cells
diverged from those found in PC-3 cells, where caspase-8 directly
activated effector caspases such as caspase-3 in the absence of any
further release of mitochondrial proapoptotic effectors [66]. In con-
trast, in MCF-7 cells, the apoptotic process was found to require
an amplification step that is mitochondria-dependent with Bid pro-
cessing, release of cytochrome c and caspase-9 activation [66].
We have postulated that the high selectivity of narciclasine for can-
cer cells might be linked at least in part to this activation of the death
receptor pathway. Normal human fibroblasts appear approximately
250-fold less sensitive to the cytotoxic effects of narciclasine, which
does not induce apoptosis in these normal fibroblasts probably due to
the absence of death receptor pathway activation [67–69]. Moreover, it
has been suggested that Amaryllidaceae alkaloids, such as narciclasine,
have a modulating activity on inflammatory reactions by inhibiting
tumor necrosis factor-alpha production in stimulated macrophages
[70]. Inflammation has been implicated in the development of many
human epithelial cancers, including those of the stomach, lung, colon,
and prostate, and tumor necrosis factor-alpha is a potent pleiotropic,
proinflammatory cytokine produced by many cells in response to in-
jury and inflammation [71].
Conclusions
Since the discovery of narciclasine, the first member of isocarbos-
tyril class of alkaloids in 1967, the search for new natural compounds
from the Amaryllidaceae plant family has resulted in the isolation of
other isocarbostyrils such as lycoricidine and pancratistatin.
To date, for the synthesis of novel isocarbostyril derivatives for the
potential discovery and development of new anticancer drug candi-
dates, the best starting material for these products is narciclasine,
which can be isolated from Narcissus species with a good yield. The
total synthesis of these products is still very complex and requires
too many steps to be developed commercially for the synthesis and
anticancer testing of novel isocarbostyrils.
The biologic activities of isocarbostyril alkaloids include excellent
in vitro and in vivo cytotoxicity against many tumor cell lines and
high selectivity for cancer cells versus normal cells. This has encour-
aged several research groups to identify new derivatives or analogs of
these isocarbostyril alkaloids for preclinical development. It is to be
hoped that continuing interest in structure modulation of these iso-
carbostyril alkaloids will provide novel promising anticancer agents.
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